Arbutus Biopharma Corp. (ABUS)
4.28
-0.20
(-4.46%)
USD |
NASDAQ |
Oct 07, 16:00
4.28
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Enterprise Value : 796.40M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 796.40M |
| October 05, 2026 | 833.95M |
| October 02, 2026 | 790.47M |
| October 01, 2026 | 812.21M |
| September 30, 2026 | 855.69M |
| September 29, 2026 | 837.90M |
| September 28, 2026 | 871.50M |
| September 25, 2026 | 869.53M |
| September 24, 2026 | 875.45M |
| September 23, 2026 | 869.53M |
| September 22, 2026 | 901.15M |
| September 21, 2026 | 899.17M |
| September 18, 2026 | 901.15M |
| September 17, 2026 | 913.00M |
| September 16, 2026 | 909.05M |
| September 15, 2026 | 911.03M |
| September 14, 2026 | 924.86M |
| September 11, 2026 | 922.89M |
| September 10, 2026 | 922.89M |
| September 09, 2026 | 932.77M |
| September 08, 2026 | 934.74M |
| September 04, 2026 | 928.82M |
| September 03, 2026 | 922.89M |
| September 02, 2026 | 918.93M |
| September 01, 2026 | 916.96M |
| Date | Value |
|---|---|
| August 31, 2026 | 914.98M |
| August 28, 2026 | 913.00M |
| August 27, 2026 | 932.77M |
| August 26, 2026 | 936.72M |
| August 25, 2026 | 938.70M |
| August 24, 2026 | 938.70M |
| August 21, 2026 | 940.67M |
| August 20, 2026 | 853.71M |
| August 19, 2026 | 895.22M |
| August 18, 2026 | 867.55M |
| August 17, 2026 | 841.86M |
| August 14, 2026 | 833.95M |
| August 13, 2026 | 816.16M |
| August 12, 2026 | 818.14M |
| August 11, 2026 | 833.95M |
| August 10, 2026 | 818.14M |
| August 07, 2026 | 826.05M |
| August 06, 2026 | 808.26M |
| August 05, 2026 | 824.07M |
| August 04, 2026 | 784.54M |
| August 03, 2026 | 772.68M |
| July 31, 2026 | 768.73M |
| July 30, 2026 | 782.57M |
| July 29, 2026 | 758.85M |
| July 28, 2026 | 782.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Insmed, Inc. | 22.56B |
| Pfizer Inc. | 208.52B |
| Gossamer Bio, Inc. | 48.91M |
| Legend Biotech Corp. | 2.941B |
| ACADIA Pharmaceuticals, Inc. | 2.515B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.143M |
| Revenue (Quarterly) | 1.014M |
| Total Expenses (Quarterly) | 6.157M |
| EPS Diluted (Quarterly) | -0.026 |
| Gross Profit Margin (Quarterly) | 98.92% |
| Profit Margin (Quarterly) | -507.2% |
| Earnings Yield | 18.30% |
| Operating Earnings Yield | 17.73% |
| Normalized Earnings Yield | 18.17 |